Similar articles

• Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.

  Lazarovits AI, Rochon J, Banks L, Hollomby DJ, Muirhead N, Jevnikar AM, White MJ, Amlot PL, Beauregard-Zollinger L, Stiller CR. Lazarovits AI, et al. Transplant Proc. 1993 Feb;25(1 Pt 1):820-2. Transplant Proc. 1993. PMID: 7679844 Clinical Trial. No abstract available.
• The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506.

  Li PK, Nicholls MG, Lai KN. Li PK, et al. Adverse Drug React Acute Poisoning Rev. 1990 Autumn;9(3):123-55. Adverse Drug React Acute Poisoning Rev. 1990. PMID: 1703724 Review. No abstract available.
• Graft failure after T cell-depleted bone marrow transplantation: clinical and immunological characteristics and response to immunosuppressive therapy.

  Bunjes D, Wiesneth M, Hertenstein B, Schmeiser T, Arnold R, Heit W. Bunjes D, et al. Bone Marrow Transplant. 1990 Nov;6(5):309-14. Bone Marrow Transplant. 1990. PMID: 1705459
• The clinical role of OKT3.

  Norman DJ. Norman DJ. Cardiol Clin. 1990 Feb;8(1):97-105. Cardiol Clin. 1990. PMID: 2407364 Review.
• Immunosuppressive drugs for kidney transplantation.

  Halloran PF. Halloran PF. N Engl J Med. 2004 Dec 23;351(26):2715-29. doi: 10.1056/NEJMra033540. N Engl J Med. 2004. PMID: 15616206 Review. No abstract available.